Solubility Rules OK! What ultrasonic mixing can do for you

Gary Allenby¹, Adrian Freeman², Tracy Martin¹ and Mike Travis³ ¹Screening Technologies and Sciences, ²New Opportunities; AstraZeneca R&D Charnwood, Loughborough, U.K. ³Microsonic Systems[™], California, U.S.A.

Introduction

A lack of compound solubility is a major hurdle in High Throughput Screening (HTS) and Lead Profiling as compounds are not always readily soluble in DMSO or remain soluble during storage. These solubility problems can at best result in unacceptable variability in assay reproducibility and at worst result in the apparent inactivity of the compound in the assay.

Additionally, it is important to ensure adequate mixing of compounds and assay reagents in low volume assays performed in small volume 384 and 1536 well plates.

We have evaluated the mixing of compounds and assay reagents in 384 and 1536 well plates using the Hendrix[™] SM100 ultrasonic microplate fluid processor from Microsonic Systems. The objectives were two fold: To determine if compound solubility in storage plates is improved following ultrasonic solubilisation. To evaluate if data fidelity in biochemical and cell-based assays is improved when ultrasonic mixing reagents in assay plates.

Hendrix SM100 ultrasonic plate mixing device (A) and under bench remote unit (B)





Well plates were ultrasonically mixed

Mixing

This LUT[™] technology is derived from Micro-Electrical-Mechanical Systems (MEMS)-based transducers, which generate ultrasonic waves when excited with RF power. An array of 384 of these transducer-elements were used in the Hendrix to enable high-speed parallel processing of microplates

Physical Chemistry

Fig. 1. Empirical determination of solubility.




Fig. 1. Almost all compounds were more soluble following ultrasonic mixing. In some cases up to 80% more compound was solubilised as determined by Area Under the Curve (AUC). There were no alterations in Molecular Weight (not shown) suggesting that sample integrity was maintained. Compound A was used as a negative control as this compound is readily soluble in DMSO.

Method: Compounds known to have solubility problems were re-suspended at 5mM in DMSO. Replica plates were generated and either ultrasonically mixed or untreated. Aliquots of compounds were diluted in Phosphate Buffered Saline containing 20mM HEPES (assay buffer) to 10µM and again ultrasonically mixed or untreated. Samples were evaluated in UV-LCMS for molecular weight and AUC as a measure of concentration.

Biochemical Assays

Fig. 2. Comparison of dose-response curves for three poorly soluble compounds screened in a Quenched FRET enzyme assay without (A) and with (B) ultrasonic mixing.




Fig. 2.A. Compounds not ultrasonically mixed did not produce an IC₅₀ and showed artefact noise within the assay - baseline is around 65% effect. However, after ultrasonic mixing (Fig. 2.B), two compounds gave an IC₅₀ (blue/red circles) and assay noise was removed. We suggest this artefact, which occurs at all compound concentrations, is due to particulate in the well that affects the measuring technology and is removed by mixing.

Method: Compounds were diluted in DMSO to 10mM and dispensed into duplicate 384 well Echo qualified plates (Labcyte). One plate was mixed with the HENDRIX SM100 and the other untreated. The Echo 555 was used to dispense compounds into the enzyme assay plate to generate a 10 point half log dilution series starting at 100 µM final concentration. Two assay plates were prepared from ultrasonically mixed compounds and two assay plates prepared from non-mixed compounds. Compounds that were previously mixed were also mixed within the assay plate with reagents and the assay run to completion.

Fig. 3 Comparison of compound activity before and after ultrasonic mixing of both the compound and assay plates in a biochemical protease assay




Fig. 3. There was general agreement in the activity of compounds in the assay in the presence or absence of mixing, however some compounds (circled) showed greater activity when ultrasonically mixed. Ultrasonic mixing of the assay components did not affect the activity of the enzyme.

Method: Six 384 well compound plates were assaved in a biochemical protease screen: 10 nL of compound were dispensed from each stock compound plate into 5µl of enzyme (assay plate) using an Echo 555 dispenser. Compound plates were then ultrasonically mixed using the HENDRIX SM100 and 10nL transferred into a second set of assay plates. The assay was initiated by the addition of 5 µl of substrate and one set of assay plates was ultrasonically mixed. All plates were incubated at room temperature for one hour and read on a Perkin Elmer Envision reader.

Cell Assay

Table. 1. Effect of ultrasonic mixing on primary human neutrophils screened within a 7-Trans-Membrane (7-TM) receptor calcium mobilisation assay in FLIPRTETRA

Table 1. Different ultrasoni conditions have little or no neutrophil responsiveness potency

Method for cell assay: Isolate Neutrophils (2 dono (density gradient centrifuga

Generate agonist dilution c (Table.1.) or EC₈₀ (Table using 7-TM ligand



Table. 2. Effect of ultrasonic mixing on the potency of antagonist compounds screened in the primary human neutrophil calcium mobilisation assay above.

Table. 2. Ultrasonic mixing improve the potency of two in this assay by as much a unit. This suggests that so compounds become more ultrasonically mixed before the assav

Summary

- mixing conditions.
- - and the potency of compounds in Lead Profiling

Conclusions

Ultrasonic mixing will be implemented in Compound Management and HTS during both the plate replication process and to enhance the mixing of reagents in wells and improve assay reproducibility.

Based on its small physical foot-print, the HENDRIX SM100 instrument will be integrated to our current Compound Management and HTS robotic systems.

	Donor number	pEC ₅₀	pEC ₅₀	pEC ₅₀	pEC ₅₀				
		No mixing	Under	Under	Under				
ic mixing			"Low" power	"Med" power	"High" power				
effect on	Donor 1	8.63	8.55	8.76	8.97				
or ligand		8.74	8.67	8.93	8.73				
	Donor 2	9.12	8.89	8.95	9.13				
		8.98	9.11	9.05	8.87				
ors) ation)	Dilute neutrophils in buffer containing Fluo-4 and dispense into 1536 plate								
curve a.2.)	Incubat (15 min	ISO (Table.1 .) se to to E (Table.2 .) Itrasonic mix Is present							
d read			-		is present				
Degree of fluorescence proportional to activation of receptor and calcium mobilisation									

	Compound	Appearance	Historical	pIC ₅₀	pIC ₅₀
g appeared to			pIC ₅₀ (average)	No mixing	Ultrasonic mixing
vo antagonists	A	Yellow - clear	6.07	5.95	6.27
as one log ome of these	В	Colourless - cloudy	6.34	6.23	7.06
e soluble when re and during	С	Yellow - clear	6.21	6.07	6.73
	D	Colourless - clear	5.49	5.38	5.52
	E	Colourless - clear	5.53	5.49	5.54

1. Ultrasonic mixing improved compound solubility and appears not to degrade sample. 2. Ultrasonic mixing improved assay reproducibility in biochemical assays probably by enhancing

3. Ultrasonic mixing does not appear to be detrimental to assay biology or human primary cells. 4. Ultrasonic mixing increased the number of compounds identified as actives in primary screening

